পদ্ধতির তুলনা করুন

	EORTC QLQ-C30	ফাইব্রোমায়ালজিয়া ইমপ্যাক্ট কোেশ্চেনিয়ার	পার্কিনসন রোগ প্রশ্নাবলী-৩৯
ক্ষেত্র	স্বাস্থ্য ফলাফল	স্বাস্থ্য ফলাফল	স্বাস্থ্য ফলাফল
পরিবার	Process / pipeline	Process / pipeline	Process / pipeline
উদ্ভবের বছর	1993	1991	1997
প্রবর্তক	Nico Aaronson et al.	Cynthia S. Burckhardt et al.	Crispin Jenkinson et al.
ধরন	Self-report quality of life questionnaire	Self-report symptom and functional impairment questionnaire	Self-report quality of life questionnaire
মৌলিক উৎস	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735.	Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age and Ageing, 26(5), 353-357.
অপর নাম	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire	PDQ-39, Parkinson's Disease Questionnaire, PDQ
সম্পর্কিত	5	4	4
সারসংক্ষেপ	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.	The PDQ-39 is the most widely used patient-reported outcome measure for Parkinson's disease quality of life. Developed by Crispin Jenkinson and colleagues in 1997, this 39-item self-report questionnaire comprehensively assesses how Parkinson's symptoms affect daily functioning, emotional well-being, stigma, social support, and cognitive-communication abilities. It is the recommended instrument in major Parkinson's disease clinical trials and forms a core component of outcome measurement in movement disorders.